Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
11:05am, Monday, 08'th Sep 2025
A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the G
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point
09:47am, Monday, 08'th Sep 2025
Bristol-Myers Squibb continues to trade below $50, creating a divergence with strong performance from its oncology and cardiovascular franchises. So, sales of its "diamond" in the treatment of non-Hod
3 Blue-Chip Dividend Stocks Yielding Over 5% – September 2025
07:32am, Monday, 08'th Sep 2025
--> --> Key Points These blue-chip dividend stocks have dependable underlying businesses. You get an equally dependable dividend yield of over 5%. Upcoming events will make their yields very juicy. Ar
Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership
09:47am, Sunday, 07'th Sep 2025
Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield. The company's innovative growth portfolio is gaining traction, offsetting legacy dec
Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good
07:15am, Saturday, 06'th Sep 2025
Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good
Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly
11:30am, Friday, 05'th Sep 2025
Bristol-Myers Squibb stock remains undervalued, even though it faces significant LOE risks through 2028. BMY's growth portfolio is gaining credence, helping to mitigate the risks due to the decline in
Bristol-Myers Squibb: Not As Cheap As It Might Seem
05:56pm, Wednesday, 03'rd Sep 2025
At first glance, Bristol-Myers Squibb appears cheap with a low P/E and strong dividend yield. GAAP earnings are consistently much lower than non-GAAP figures, reflecting costs which may limit cash ava
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
11:11am, Tuesday, 02'nd Sep 2025
Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.
7 Big Yields From The Beat-Up Healthcare Sector
10:52am, Monday, 01'st Sep 2025
Healthcare stocks haven't moved since the April lows. As contrarian investors, this neglect piques our interest.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Monday, 01'st Sep 2025
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
8 'Safer' Dividend Buys In Barron's 23 Better Bets (BBB) Than T-Bills August Report
11:18am, Sunday, 31'st Aug 2025
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge d
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology Congress 2025
Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
06:59am, Friday, 29'th Aug 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September
8 Ideal 'Safer' Dividend Dogs To Buy From 60 August Graham Value All-Stars
03:51am, Thursday, 28'th Aug 2025
I use YCharts' Value Score and Ben Graham Formula to identify large-cap value stocks offering strong intrinsic value and stable dividends. Analyst forecasts suggest top-ten GASV 'Dogs' could deliver 1
Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
11:06am, Wednesday, 27'th Aug 2025
Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.
